Xeris Pharmaceuticals (NASDAQ:XERS) Issues Quarterly Earnings Results

Xeris Pharmaceuticals (NASDAQ:XERS) posted its quarterly earnings results on Thursday. The company reported ($1.22) EPS for the quarter, beating the consensus estimate of ($1.23) by $0.01, Fidelity Earnings reports. Xeris Pharmaceuticals had a negative net margin of 4,876.50% and a negative return on equity of 107.65%. The company had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.20 million.

NASDAQ:XERS opened at $8.02 on Friday. Xeris Pharmaceuticals has a one year low of $6.85 and a one year high of $25.49. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.00 and a current ratio of 6.00. The firm has a market cap of $236.68 million, a price-to-earnings ratio of -1.61 and a beta of -0.49. The firm’s fifty day moving average is $8.71 and its two-hundred day moving average is $10.49.

XERS has been the topic of several recent research reports. ValuEngine lowered shares of Xeris Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, September 30th. Mizuho reaffirmed a “buy” rating and issued a $22.00 price target on shares of Xeris Pharmaceuticals in a report on Friday. Finally, Royal Bank of Canada set a $18.00 price target on shares of Xeris Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 7th.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

In other Xeris Pharmaceuticals news, insider Steven Prestrelski sold 27,700 shares of the company’s stock in a transaction on Friday, October 11th. The shares were sold at an average price of $9.00, for a total value of $249,300.00. 7.43% of the stock is currently owned by corporate insiders.

Xeris Pharmaceuticals Company Profile

Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.

Featured Story: Commodities

Earnings History for Xeris Pharmaceuticals (NASDAQ:XERS)

Leave a Reply

Your email address will not be published. Required fields are marked *